Loading...
OTCM
THER
Market cap6kUSD
Jul 28, Last price  
0.00USD
Name

Theralink Technologies Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
513.34%
Rev. gr., 5y
%
Revenues
607k
+6.85%
0000266,808781,05077,93824254740000181,229505,604567,905606,796
Net income
-31m
L+142.43%
-50,890-65,411-53,957-58,201-1,049,087-952,543-315,938-757,403-453,879-990,396-2,013,632-20,513,1386,468,325-11,197,642-3,211,485-5,592,743-12,749,262-30,907,505
CFO
-6m
L+7.15%
-30,215-38,340-53,958-44,560-737,368-606,152-637,621-372,227-418,212-851,841-1,544,003-2,294,341-1,679,406-1,171,131-3,470,755-4,780,930-5,389,695-5,774,855

Profile

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
URL
https://oncbiomune.com/
IPO date
Apr 23, 2007
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑122018‑122017‑122016‑122015‑12
Income
Revenues
607
6.85%
568
12.32%
Cost of revenue
9,272
12,208
Unusual Expense (Income)
NOPBT
(8,665)
(11,640)
NOPBT Margin
Operating Taxes
16,707
7
Tax Rate
NOPAT
(25,371)
(11,647)
Net income
(30,908)
142.43%
(12,749)
127.96%
Dividends
(26)
(199)
Dividend yield
0.48%
0.97%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
18,631
1,431
Long-term debt
2,323
4,216
Deferred revenue
Other long-term liabilities
Net debt
19,955
5,249
Cash flow
Cash from operating activities
(5,775)
(5,390)
CAPEX
(163)
(132)
Cash from investing activities
(163)
(132)
Cash from financing activities
6,542
5,601
FCF
(7,704)
(13,662)
Balance
Cash
998
397
Long term investments
Excess cash
968
369
Stockholders' equity
(93,140)
(59,193)
Invested Capital
76,015
59,766
ROIC
ROCE
50.60%
EV
Common stock shares outstanding
6,151,500
5,881,207
Price
0.00
-74.29%
0.00
-93.00%
Market cap
5,536
-73.10%
20,584
-92.33%
EV
25,492
28,834
EBITDA
(8,457)
(11,449)
EV/EBITDA
Interest
16,907
1,095
Interest/NOPBT